本帖最后由 老马 于 2013-3-13 13:43 编辑
: ~3 \' S) o4 a9 { S& q# u
9 U) N- S4 Z8 {. e健择（吉西他滨）+顺铂+阿瓦斯汀
* p5 {% v3 O5 e, u! V; {7 z Gemzar +Cisplatin + Avastin" o7 a6 A% k/ M; B; j& ?5 p
http://annonc.oxfordjournals.org/content/21/9/1804.full
3 ^& m. P$ B- V8 mOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: C8 M; g' r% {" `" r2 WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ [* z7 @4 I/ D/ HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ W3 c! V6 x3 F- J0 F$ J( w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 277)
% g2 Y! t8 G' h& g2 w3 n6 d6 s
华为网盘附件：( k" X K1 m. O' Z
【华为网盘】ava.JPG& w0 L2 ~8 T; j
|
显身卡
